Focus: AstraZeneca is a global Big Pharma with 89,900 employees headquartered in Cambridge, UK, operating across oncology, cardiovascular, respiratory, immunology, and rare diseases. The company maintains a diversified portfolio of small molecules, vaccines, and biologics with significant market presence.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow AstraZeneca to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AstraZeneca
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AstraZeneca's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product driving 37% of company revenue with extended patent protection until 2041, critical to career stability.
Second-largest revenue contributor now facing loss-of-exclusivity, signaling near-term commercial headwinds.
Oncology franchise cornerstone with stable peak sales and patent protection through 2036.
Leading EGFR inhibitor with extended LOE through 2042, benefiting from 60 active trials and Phase 4 development.
Emerging respiratory franchise player with patent protection through 2038 and strong growth trajectory.
Cardiovascular franchise anchor with mid-lifecycle peak sales and patent extension through 2036.
PARP inhibitor with 144 active trials demonstrating expansion across cancer indications; LOE in 2031 presents near-term patent cliff risk.
Only product on explicit patent cliff ($284M revenue at risk by 2031), requiring pipeline replacement strategy.
108 discontinued, 23 duplicate formulations not shown
+16 more products with revenue data
+2 more
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: A systematic literature review.
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.
+12 more products
+2 more
+2 more
+2 more
+2 more
+2 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo